← BackAgomAb Therapeutics NV · BiotechAGMB
Low riskNext report: Not enough history
The short versionA company. Insiders are buying.
Going well
- No warning signs in its SEC filings
Money moves
- A top executive bought $400K of shares with their own money in the last 30 days
- Institutions added 18% to their holdings in the quarter ending June 2026 (13 bought, 13 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$8.54-5.6% that day
Latest insider buy: A director bought at $8.88 on Oct 21. The stock is now $8.54, -3.8% since.
- Company value
- $292M
- Share price times all shares
From AGMB's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Insider rating
Last 90 days
90Strong buying
- 3 insiders bought $400K
- Top executive buying (Chief Executive Officer)
- David R Epstein grew their stake 66.7%
- New position opened
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
Weekly insider trend13 weeks agoBoughtSoldThis week
Filing buzz
Last 7 days vs normal
48/ 100
- This week
- 1
- Normal week
- 1.1
- vs normal
- 0.9x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+17.9%Institutions added 17.9% to their holdings. 13 bought, 13 sold. 2 quarters of net buying in a row.
Shares held by institutions27.5M
Sep '24Jun '26
Shares outstandingLatest reported
34MNext reportNot enough history
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days Bought$400K3 insiders
Sold$00 insiders
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|
David R EpsteinDirector | Buy | 10K | $8.88 | $89K | 25K | |
- +66.7% of their holdings
- $8.86 to $8.90 across 2 trades
- Filed 1 day after
|
David R EpsteinDirector | Buy | 5K | $8.90 | $45K | 15K | |
- +50% of their holdings
- Filed 1 day after
|
Tim Jasper KnotnerusChief Executive Officer | Buy | 11K | $8.58 | $94K | 22K | |
- +101.6% of their holdings
- $8.48 to $8.70 across 2 trades
- Traded Oct 5 to Oct 6
- Also Director
- Filed 1 day after
|
Pierre Thadee Victor KemulaChief Financial Officer | Buy | 10K | $8.59 | $86K | 10K | |
- New position, first shares owned
- $8.54 to $8.67 across 3 trades
- Filed 1 day after
|
David R EpsteinDirector | Buy | 10K | $8.64 | $86K | 10K | |
- New position, first shares owned
- $8.57 to $8.70 across 2 trades
- Traded Oct 5 to Oct 6
- Filed 1 day after
|
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
BoughtDavid R EpsteinDirector
10,000 shares at $8.88 avg ($8.86 to $8.90) · $89K
- +67% of holdings
- Now owns 25,000 shares
- 2 transactions
- Filed 1 day after trade
BoughtDavid R EpsteinDirector
5,000 shares at $8.90 · $45K
- +50% of holdings
- Now owns 15,000 shares
- Filed 1 day after trade
BoughtTim Jasper KnotnerusChief Executive Officer, Director
11,000 shares at $8.58 avg ($8.48 to $8.70) · $94K
- +102% of holdings
- Now owns 21,823 shares
- 2 transactions
- Filed 1 day after trade
BoughtPierre Thadee Victor KemulaChief Financial Officer
10,000 shares at $8.59 avg ($8.54 to $8.67) · $86K
- New position
- Now owns 10,000 shares
- 3 transactions
- Filed 1 day after trade
BoughtDavid R EpsteinDirector
10,000 shares at $8.64 avg ($8.57 to $8.70) · $86K
- New position
- Now owns 10,000 shares
- 2 transactions
- Filed 1 day after trade
Stock awardNaimish PatelDirector
56,328 shares
- Now owns 56,328 shares
- Exercise price $13.94
- Stock Option (Right to Buy)
- Filed 4 days after trade
Stock awardMarino GarciaDirector
57,482 shares
- Now owns 57,482 shares
- Exercise price $13.94
- Stock Option (Right to Buy)
- Filed 4 days after trade